Related Experiment Video
Updated: Aug 9, 2026
Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models
Published on: January 14, 2020
Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer
Yuqing Zhang1, Courtney W Houchen1, Min Li1,2
1College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Abstract:
The patient-derived organoids (PDO) platform recapitulates the phenotype, genotype, and molecular characteristics of primary tumors. High-throughput drug screening in terms of pharmacotyping using standard-of-care chemotherapy agents in the PDO platform has shown promising sensitivities to guide precision medicine for individual patients with pancreatic ductal adenocarcinoma (PDAC) within a clinically relevant time frame. See related article by Seppälä et al., p. 3296.
Insights
Patient-derived organoids (PDO) effectively model pancreatic cancer's characteristics. This platform shows promise for high-throughput drug screening to guide precision medicine for pancreatic ductal adenocarcinoma (PDAC) patients.
Area of Science:
- Oncology
- Translational Medicine
- Genomics
Background:
- Patient-derived organoids (PDOs) are established as reliable models that recapitulate the phenotypic, genotypic, and molecular heterogeneity of primary tumors.
- Pancreatic ductal adenocarcinoma (PDAC) presents significant therapeutic challenges due to its aggressive nature and limited treatment options.
Discussion:
- High-throughput drug screening using PDOs allows for pharmacotyping with standard-of-care chemotherapy agents.
- This approach demonstrates promising drug sensitivities, offering a potential strategy for personalized treatment selection.
Key Insights:
- PDOs accurately reflect individual tumor characteristics, enabling predictive drug response assessments.
- Pharmacotyping in PDOs can identify effective chemotherapy agents for individual PDAC patients.
- The PDO platform facilitates precision medicine by providing clinically relevant therapeutic guidance in a timely manner.
Outlook:
- Further validation of PDO-based pharmacotyping in clinical settings is warranted.
- Expansion of PDO applications to novel therapeutic agents and combination therapies is anticipated.
- This platform holds potential for accelerating the development of targeted therapies for PDAC.
